AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 983794
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g niceritrol given twice daily (1.5 g X 2)
Trial: 12668405
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Trial: 17156174
Drug: Dihydrocodeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine (30 mg or 60 mg tablets)
Trial: 17156174
Drug: Methadone mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone mixture (1 mg/ml)
Trial: 10699069
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy alone (n = 348)
Trial: 10699069
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with postoperative radiotherapy (n = 346)
Trial: 10699069
Drug: 5-FU plus
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU plus LV chemotherapy in male patients (n = 200)
Trial: 10699069
Drug: MOF chemotherapy
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MOF chemotherapy in male patients (n = 207)
Trial: 30053896
Drug: PF-06438179/GP1111 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06438179/GP1111 (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Trial: 30053896
Drug: Infliximab-EU (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab-EU (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Trial: 30053896
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PF-06438179/GP1111 and infliximab-EU)
Trial: 26843085
Drug: Multivitamin supplement
RxNorm normalized name: Vi-Daily Multivitamin Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 3 months
Trial: 26843085
Drug: Multivitamin supplement
RxNorm normalized name: Vi-Daily Multivitamin Supplement Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 12 months
Trial: 20224262
Drug: 3 instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 instillations of 1% silver nitrate solution
Trial: 20224262
Drug: 9 instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 instillations of 1% silver nitrate solution
Trial: 17391132
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg b.i.d.
Trial: 17391132
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg b.i.d.
Trial: 10683057
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d of androstenedione
Trial: 10683057
Drug: 300 mg/d
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/d of androstenedione
Trial: 10683057
Drug: 0 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/d of androstenedione (control)
Trial: 8364949
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg intramuscularly every 3 to 6 hours as needed, followed by 10 mg every 4 to 6 hours)
Trial: 8364949
Drug: Meperidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (100 mg intramuscularly every 3 to 6 hours as needed, followed by acetaminophen/codeine (600 mg/60 mg) orally every 4 to 6 hours)
Trial: 20584668
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg intravenously, repeated at 24 and 48 hours post-operation
Trial: 10391601
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (17.5 mg)
Trial: 10391601
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.6 mg) and intrathecal bupivacaine (17.5 mg)
Trial: 6658432
Drug: Pyrazinamide (PZA)
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide (PZA) at 25 mg/kg body weight
Trial: 6658432
Drug: Ethambutol (EMB)
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethambutol (EMB) at 25 mg/kg body weight
Trial: 29944706
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing (DSW) and daily activity tracking (DAT)
Trial: 29944706
Drug: Daily activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activity tracking (DAT)
Trial: 24946564
Drug: Orthopedics lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopedics lotion fumigation treatment (treatment group)
Trial: 24946564
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate intra-articular injection (control group)
Trial: 24946564
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (treatment and control)
Trial: 23575046
Drug: Preemptive fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 125 μg (2.5 ml)
Trial: 23575046
Drug: Preemptive fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 150 μg (3 ml)
Trial: 23575046
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (0.5 ml) prior to fentanyl 150 μg (3 ml)
Trial: 19721169
Drug: Intracapsular injection
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracapsular injection of 8 ml of 2% lidocaine
Trial: 17961836
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (group NSI)
Trial: 17961836
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate infusion (group RLI)
Trial: 9025819
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group - CTL)
Trial: 1497157
Drug: Meperidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (75 mg)
Trial: 6206687
Drug: Metrizamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrizamide (300 mg I/ml)
Trial: 27489241
Drug: Anti-NKG2D (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-NKG2D (2 mg/kg, single subcutaneous dose)
Trial: 26241597
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction therapy (n=58)
Trial: 26241597
Drug: Present-centered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered group therapy (n=58)
Trial: 23508680
Drug: Psychosocial and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial and/or pharmacotherapy (sertraline)
Trial: 21644308
Drug: Gaitianli (Oyster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaitianli (Oyster Shell and Calcium Carbonate Chewable) tablets
Trial: 10232502
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg, increased to 160 mg after 4 weeks)
Trial: 10232502
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg, increased to 100 mg after 4 weeks)
Trial: 8674154
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of dolasetron (1.8 mg/kg)
Trial: 8674154
Drug: Multiple-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose regimen of dolasetron (0.6 mg/kg each, total 1.8 mg/kg)
Trial: 1855018
Drug: Steroid with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid with distension
Trial: 1855018
Drug: Steroid only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid only
Trial: 6411441
Drug: Dobutamine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (7 micrograms/kg . min) + Nitroglycerin (1.5-3.0 mg/h)
Trial: 6411441
Drug: Nitroglycerin (3.0-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (3.0-6.0 mg/h)
Trial: 6411441
Drug: Nitroglycerin (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (increased dose)
Trial: 31541008
Drug: Two-level, variable-volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-level, variable-volume epidural blood patch (EBP)
Trial: 26743587
Drug: Polypill (containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (containing aspirin 75 mg, simvastatin 20 mg, lisinopril 10 mg and hydrochlorothiazide 12.5 mg)
Trial: 23080351
Drug: Liposome bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome bupivacaine 89 mg
Trial: 23080351
Drug: Liposome bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome bupivacaine 155 mg
Trial: 23080351
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl 50 mg
Trial: 20206430
Drug: Cabergoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5 mg weekly during the second half of the cycle)
Trial: 20206430
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg daily during the second half of the cycle)
Trial: 10334140
Drug: Fluticasone at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone at 4 mg via MDI spacer
Trial: 10334140
Drug: Fluticasone at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone at 2 mg via MDI spacer
Trial: 10334140
Drug: Budesonide at
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide at 4 mg via MDI spacer
Trial: 10334140
Drug: Budesonide at
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide at 2 mg via MDI spacer
Trial: 10334140
Drug: Beclomethasone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone at 4 mg via MDI spacer
Trial: 26083771
Drug: Creatine loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine loading (20 g·d⁻¹ for 5 days)
Trial: 21809733
Drug: Kangaroo care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo care (KC) and live harp music therapy
Trial: 17284748
Drug: Synbiotic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic preparation (SYN1 + Lactobacillus rhamnosus GG + Bifidobacterium lactis Bb12)
Trial: 15462618
Drug: Confidence-accuracy calibration
RxNorm normalized name: Phisoderm Clear Confidence Body Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence-accuracy calibration for sequential mini-lineups
Trial: 9725476
Drug: Test formulations
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulations (two new formulations)
Trial: 9725476
Drug: Test capsule
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test capsule
Trial: 25387843
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of vancomycin (1 mg/0.1 ml)
Trial: 25387843
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of cefuroxime (1 mg/0.1 ml)
Trial: 18642209
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) combined with intravitreal injection of bevacizumab (1.25 mg)
Trial: 18642209
Drug: Standard photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard photodynamic therapy (PDT)
Trial: 8669166
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg/week in association with Ursodeoxycholic acid (UDCA) 500 mg/day
Trial: 31550251
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Suicide Prevention therapy
Trial: 23099329
Drug: NDV-3 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDV-3 (30 μg Als3p)
Trial: 23099329
Drug: NDV-3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDV-3 (300 μg Als3p)
Trial: 15736118
Drug: acarbose (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acarbose (150 mg/d)
Trial: 15736118
Drug: voglibose (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.9 mg/d)
Trial: 15736118
Drug: voglibose (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: voglibose (0.3 mg)
Trial: 11756072
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein (ISP) containing 56 mg isoflavones (ISP56)
Trial: 11756072
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein (ISP) containing 90 mg isoflavones (ISP90)
Trial: 2515527
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 micrograms daily)
Trial: 2515527
Drug: De‐Nol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De‐Nol (5 ml four times a day diluted with 15 ml of water)
Trial: 30595326
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg
Trial: 30595326
Drug: Atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg
Trial: 23918588
Drug: Resveratrol (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (3g daily for 12 weeks)
Trial: 2286438
Drug: Steam therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam therapy in a cloth tent (Study Group)
Trial: 2286438
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no steam therapy)
Trial: 26343332
Drug: RED-D (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RED-D (modified brief Cognitive Behavioral Therapy delivered telephonically by a mental health professional)
Trial: 25208663
Drug: 380 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380 g of farmed Atlantic salmon fillets per week for 15 weeks
Trial: 25208663
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g of salmon oil per week for 15 weeks
Trial: 19963031
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (9 g daily for 12 weeks)
Trial: 17496286
Drug: PCI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI treatment of re-infarction
Trial: 17496286
Drug: Regional differences
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional differences in treatment
Trial: 12004808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine (1 mg x m(‐1)) and ketamine (0.75 mg x m(‐1)) via PCAS
Trial: 12004808
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg x m(‐1)) via PCAS
Trial: 2189149
Drug: High-dose alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alternate-day prednisolone
Trial: 7322959
Drug: Indapamide, 2.5
RxNorm normalized name: Indapamide, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide, 2.5 mg daily
Trial: 7322959
Drug: Cyclopenthiazide, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopenthiazide, 0.5 mg daily
Trial: 31694568
Drug: ROTEM®-guided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROTEM®-guided treatment in patients with long CPB-times (> 115 min.; n = 55)
Trial: 24048773
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily for 3 days
Trial: 24048773
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice daily for 3 days
Trial: 19533304
Drug: Intravenous moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moderate doses of human recombinant Epo (epoietin-alpha, 100 or 200 IU/kg/die)
Trial: 31580316
Drug: FITÂ® Lady
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FITÂ® Lady patch (active patch)
Trial: 28987358
Drug: Fermented plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented plant extract (FPE) 60 mL
Trial: 21871686
Drug: Saxagliptin 5mg
RxNorm normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5mg daily plus metformin
Trial: 18974285
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/day and Olmesartan 40 mg/day administered separately for 10 days
Trial: 18974285
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of Amlodipine/Olmesartan 10 mg/40 mg
Trial: 18974285
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet taken 30 minutes after a high-fat breakfast
Trial: 18974285
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 10 mg to 40 mg with Amlodipine 5 mg to 10 mg
Trial: 17102570
Drug: Colestimide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide (3 g/day)
Trial: 14767300
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg controlled release melatonin at night
Trial: 31923074
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (5%) applied at least 10 minutes before biopsy
Trial: 31923074
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (1%) administered at least 1 minute prior to biopsy
Trial: 31923074
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (5%)
Trial: 31923074
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (1%)
Trial: 29299888
Drug: Pudendal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal nerve block (PDB-Group) with 0.3 ml/kg 0.25% bupivacaine
Trial: 29299888
Drug: Penile nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penile nerve block (PNB-Group) with 0.3 ml/kg 0.25% bupivacaine
Trial: 11094866
Drug: Nicotrol NS
RxNorm normalized name: Nicotrol NS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotrol NS (3 mg nicotine)
Trial: 1317765
Drug: L-tryptophan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (2 g)
Trial: 20099987
Drug: Ziprasidone 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 320 mg/day
Trial: 20099987
Drug: Haloperidol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.5 mg/day
Trial: 20099987
Drug: Haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 15 mg/day
Trial: 8275889
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg/day
Trial: 19026036
Drug: Midostaurin 25
RxNorm normalized name: midostaurin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 25 mg twice daily
Trial: 19026036
Drug: Midostaurin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 50 mg twice daily